Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urinary Kallidinogenase in Acute Ischemic Stroke with Type 2 Diabetes
NCT06085378Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Jan 2024
- Primary completion
- Dec 2026
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial in ischemic stroke comparing Urinary Kallidinogenase with Placebo (2 arms). Primary endpoint: Proportion of patients with modified Rankin Scale 0-2 at 90 days. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
Human urinary kallidinogenase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT06085378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06085378.